APLMW Projected Dividend Yield
Apollomics Inc ( NASDAQ : APLMW )Apollomics is a clinical-stage biopharmaceutical company. Co. has a pipeline of nine drug candidates across multiple programs, six of which are in the clinical stage of development. Co.'s primary programs include investigating its main product, vebreltinib (APL-101), a selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations; and developing an anti-cancer enhancer drug candidate, uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers. 20 YEAR PERFORMANCE RESULTS |
APLMW Dividend History Detail APLMW Dividend News APLMW Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |